Pommier Y, Pourquier P, Fan Y, Strumberg D
Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, Bethesda, MD 20892-4255, USA.
Biochim Biophys Acta. 1998 Oct 1;1400(1-3):83-105. doi: 10.1016/s0167-4781(98)00129-8.
DNA topoisomerase I is essential for cellular metabolism and survival. It is also the target of a novel class of anticancer drugs active against previously refractory solid tumors, the camptothecins. The present review describes the topoisomerase I catalytic mechanisms with particular emphasis on the cleavage complex that represents the enzyme's catalytic intermediate and the site of action for camptothecins. Roles of topoisomerase I in DNA replication, transcription and recombination are also reviewed. Because of the importance of topoisomerase I as a chemotherapeutic target, we review the mechanisms of action of camptothecins and the other topoisomerase I inhibitors identified to date.
DNA拓扑异构酶I对细胞代谢和存活至关重要。它也是一类新型抗癌药物的作用靶点,这类药物对先前难治的实体瘤具有活性,即喜树碱类药物。本综述描述了拓扑异构酶I的催化机制,特别强调了代表酶催化中间体和喜树碱作用位点的切割复合物。还综述了拓扑异构酶I在DNA复制、转录和重组中的作用。由于拓扑异构酶I作为化疗靶点的重要性,我们综述了喜树碱类药物以及迄今已鉴定出的其他拓扑异构酶I抑制剂的作用机制。